|
|
Cancer Therapeutics CRC Enters Collaboration with Major US Academic Medical Center
By Cancer Therapeutics CRC Pty Ltd
Publication date : Wednesday, 07 October 2009
Cancer Therapeutics CRC Pty Ltd, Melbourne, Australia (CTx) today announced a collaboration with
|
|  Duke University, North Carolina, USA (Duke) to discover and develop new drugs for the treatment of many forms of cancer, based on research undertaken by the laboratory of Duke Professor Patrick Casey.
Professor Casey and his team at Duke have been investigating lipid signaling pathways and the role of lipid metabolising enzymes in cancer for many years and have developed a series of promising new inhibitors of these enzymes. CTx has taken an exclusive license to these inhibitors and will initiate a drug development program to bring these early stage compounds toward the clinic.
This adds to CTx’s international collaborations and was greatly facilitated by CTx’s commercial partner, Cancer Research Technology Ltd of the UK and its US subsidiary, Cancer Research Technology Inc.
CTx’s CEO, Tony Evans commented that collaborating with an academic medical center of Duke’s caliber is a major expansion of CTx’s capabilities in partnering with overseas cancer researchers in order to source the most promising novel targets for CTx’s drug discovery projects.
About Cancer Therapeutics
Cancer Therapeutics CRC Pty Ltd has been formed through a collaboration between a number of Australia’s leading research institutions and commercial organisations for the purposes of cancer drug discovery and development. It is funded under the Australian Government’s CRC scheme.
The objective of the Company is to take novel or relatively novel molecular targets or early stage compounds from research institutes or biotech companies in Australia, or overseas, undertake hit discovery, hit to lead development and lead optimization, to produce high quality pre-clinical trial candidates for further development through commercialization.
Want to read more?
TB Drug Discovery Initiative Announces New Collaborator
SFDA Approval of High-dose (36,000 IU) EPIAO
Identification of Drug Target for Friedreich's Ataxia
|
|
